司美格鲁肽联合替米沙坦治疗早期糖尿病肾病临床研究

Clinical Study of Semaglutide Combined with Telmisartan in the Treatment of Early Diabetic Nephropathy

目的探讨司美格鲁肽联合替米沙坦治疗早期糖尿病肾病(DN)的临床疗效。方法选取医院2021年6月至2022年6月收治的早期DN患者90例,按随机数字表法分为观察组和对照组,各45例。对照组口服替米沙坦片治疗,观察组在对照组治疗基础上加用司美格鲁肽皮下注射,均治疗3个月。结果观察组总有效率为88.89%,显著高于对照组的71.11%(P<0.05);观察组治疗后的空腹血糖、餐后2 h血糖、糖化血红蛋白、血尿素氮、血肌酐、白细胞介素6、肿瘤坏死因子-α、单核细胞趋化蛋白-1水平均显著低于对照组,估算肾小球滤过率显著高于对照组(P<0.05);观察组和对照组治疗期间不良反应发生率相当(15.56%比8.89%,P>0.05)。结论司美格鲁肽联合替米沙坦治疗早期DN疗效显著,能维持患者的血糖稳定,减轻机体炎性反应,保护肾功能,且安全性高。

Objective To investigate the clinical efficacy of semaglutide combined with telmisartan in the treatment of early diabetic nephropathy(DN).Methods A total 90 early DN patients admitted to the hospital from June 2021 to June 2022 were selected and divided into the observation group and the control group by the random number table method,with 45 cases in each group.The patients in the control group were treated with Telmisartan Tablets orally,on this basis,the patients in the observation group were treated with subcutaneous injection of semaglutide.Both groups were treated for three months.Results The total effective rate in the observation group was 88.89%,which was significantly higher than 71.11%in the control group(P<0.05).After treatment,the levels of fasting blood glucose,2 h postprandial blood glucose,glycosylated hemoglobin,blood urea nitrogen,serum creatinine,interleukin-6,tumor necrosis factor-α,and monocyte chemoattractant protein-1 in the observation group were significantly lower than those in the control group,while the estimated glomerular filtration rate in the observation group was significantly higher than that in the control group(P<0.05).During treatment,the incidence of adverse reactions in the observation group was comparable to that in the control group(15.56%vs.8.89%,P>0.05).Conclusion Semaglutide combined with telmisartan is effective and safe in the treatment of early DN,which can maintain the stability of blood sugar,reduce inflammatory reactions,and protect renal function.